The locus-specific enhancer activity of the class I major histocompatibility complex interferon-responsive element is associated with a gamma-interferon (IFN)-inducible factor distinct from STAT1alpha, p48, and IFN regulatory factor-1.

The Journal of Biological Chemistry
A N Vallejo, L R Pease

Abstract

Recent analyses of the upstream regulatory regions of the class I major histocompatibility complex genes in higher primates provided a generalized structural basis for the differential expression of A- and B-locus gene products in response to specific physiological stimulus. Among the regulatory sequences that differ between the loci is the interferon-responsive element (IRE). While the B-IRE is conserved, the A-IREs have species-specific sequence variation. We previously demonstrated that the B-IRE was an interferon (IFN)-inducible enhancer, whereas none of the A-IREs were functional. In the present study, we examined the biochemical basis for the enhancer activity of the conserved B-IRE and found that this may be attributed to a novel gamma-IFN-inducible factor. This factor accumulated in nuclei of cells within minutes of exposure to gamma-IFN. Its appearance was independent of de novo protein synthesis. However, it was not detected in nuclei of cells treated with herbimycin A, suggesting that its appearance depends on a protein kinase activation pathway. Supershift assays indicated that it was distinct from STAT1alpha, IFN regulatory factor-1, and p48, transcription factors known to bind IRE-like sequences found in regulator...Continue Reading

References

Dec 1, 1991·Immunology Today·D J Maudsley, J D Pound
Aug 1, 1990·Immunology Today·B David-WatineP Kourilsky
Jan 1, 1990·Annual Review of Biochemistry·P J Bjorkman, P Parham
Jan 1, 1990·Annual Review of Immunology·D A LawlorP Parham
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·X Y FuJ E Darnell
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·D S KesslerJ E Darnell
Feb 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·L E ReidI M Kerr
Sep 1, 1989·The Journal of Experimental Medicine·R VersteegP I Schrier
Feb 1, 1995·Immunological Reviews·A N Vallejo, L R Pease
Dec 1, 1994·PCR Methods and Applications·A N VallejoL R Pease
Jul 4, 1995·International Journal of Cancer. Journal International Du Cancer·M P ImrehM G Masucci
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K D KhanA L Bothwell
Feb 1, 1995·Molecular and Cellular Biology·V BrikenP Staeheli
Jan 1, 1994·Advances in Immunology·C RothP Kourilsky
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J GirdlestoneC Milstein
Oct 1, 1993·Immunology Today·F GarridoP L Stern
Jan 1, 1994·Advances in Immunology·D H Raulet
Jan 1, 1993·Journal of Virology·L FietteC P Rossi

❮ Previous
Next ❯

Citations

Oct 11, 2003·Pharmacology & Therapeutics·Dhananjaya V Kalvakolanu
Dec 27, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Dhananjaya V Kalvakolanu, Sanjit K Roy
Feb 26, 2015·Immunology Letters·Yue PangQingwei Li
Nov 9, 2000·The Journal of Biological Chemistry·A N VallejoJ J Goronzy
Feb 8, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·David R Johnson
Jun 7, 2002·The Journal of Biological Chemistry·Junbo HuDhananjaya V Kalvakolanu

❮ Previous
Next ❯

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.